Results 201 to 210 of about 22,920 (247)
Computational Investigation of Montelukast and Its Structural Derivatives for Binding Affinity to Dopaminergic and Serotonergic Receptors: Insights from a Comprehensive Molecular Simulation. [PDF]
Pharmaceuticals (Basel)Alotaiq N, Dermawan D.
europepmc +1 more source
Omalizumab pretreatment in a case of pediatric carboplatin desensitization. [PDF]
Pediatr Allergy ImmunolBrozyna JR +4 more
europepmc +1 more source
Montelukast Use and the Risk of Neuropsychiatric Adverse Events in Children.
JAMA PediatrWintzell V +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 1998
Montelukast is a selective antagonist of the leukotriene D4 (LTD4) receptor. In patients with asthma, montelukast 5 to 250 mg/day attenuated LTD4-induced bronchoconstriction and, at a dosage of 10 mg, significantly reduced early and late airway response to allergen (dust mite extract) relative to placebo.
A, Markham, D, Faulds
+5 more sources
Montelukast is a selective antagonist of the leukotriene D4 (LTD4) receptor. In patients with asthma, montelukast 5 to 250 mg/day attenuated LTD4-induced bronchoconstriction and, at a dosage of 10 mg, significantly reduced early and late airway response to allergen (dust mite extract) relative to placebo.
A, Markham, D, Faulds
+5 more sources